-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of August 8, Zhongsheng Pharmaceutical released its 2022 semi-annual repo.
In the first half of the year, it achieved an operating income of 326 billion yuan and a non-net profit of 188 million yuan attributable to the pare.
The research and development investment was 84389 million yuan, a year-on-year increase of 22
Under the continuous investment in research and development, Zhongsheng Pharmaceutical has a steady development momentum, of which the Chinese patent medicine business achieved sales of 853 million yuan, a year-on-year increase of 7
It is reported that the company also attaches great importance to the secondary development of traditional Chinese medicine and the development of high-end high-quality decoction piec.
In addition, the traditional Chinese medicine production workshop of the first phase of its Zhaoqing production base project has been officially put into operation, and the second phase of the traditional Chinese medicine extraction workshop is undergoing civil engineering construction as plann.
The construction of this project will help the company to grasp the cooperation opportunities of major industrial projects such as biomedicine and modern Chinese medicine, and consolidate the advantages of the pharmaceutical industry cha.
The near future is the performance disclosure period for the first half of 202 The semi-annual reports of traditional Chinese medicine companies are being released one after another, and the R&D investment situation has surfac.
On the whole, due to the influence of the centralized procurement of proprietary Chinese medicines and the promotion of the national policy to encourage the innovative development of traditional Chinese medicines, many traditional Chinese medicine companies actively invested in innovation and transformation in the first half of the year, and their R&D investment increased significant.
In addition to Zhongsheng Pharmaceutical, the annual report also shows that Chinese medicine companies have increased their enthusiasm for R&D investme.
For example, Yunnan Baiyao intends to increase R&D investment in recent yea.
On June 27, the company stated on the investor interaction platform that in recent years, the company has continued to increase R&D investment in various business secto.
From 2017 to 2021, the company's R&D investment amounts were 84 million yuan, 110 million yuan, 174 million yuan, 181 million yuan, and 331 million yu.
Pien Tze Huang is also accelerating the research and development of new drugs, continuously increasing investment, and carrying out the secondary development of advantageous varieties with Pien Tze Huang as the core, as well as the research and development of new products such as innovative traditional Chinese medicines, classic prescriptions, and innovative chemical dru.
At the beginning of this year, in order to further expand production capacity, enrich product varieties, increase R&D investment and market development efforts, the company also plans to spend more than 4 billion yuan to invest in capacity expansion projects to further improve the company's automation and intelligence lev.
Product quality management efficiency, fully meet market demand, and ensure long-term and stable development of the enterprise
In 2021, Pien Tze Huang's R&D investment will increase by 1052% year-on-ye.
In addition, in 2021, the R&D investment will increase by more than 100% year-on-year, such as Jichuan Pharmaceutic.
The company's research and development expenses in 2021 will be 523 million yuan, accounting for 86% of reven.
It is reported that in 2021, Jichuan Pharmaceutical will be based on traditional Chinese medicine, generic drugs, and improved new dru.
Drug production approval for Gongliuqing table.
Jichuan Pharmaceutical stated that it will increase investment in research and development, enrich product lines, and strive to improve sustainable development and profitabili.
According to data from Flush, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the companies’ R&D investments have achieved year-on-year grow.
Behind the increasing investment in research and development by pharmaceutical companies, it can be seen that innovation has become an urgent issue facing Chinese medicine companies, forcing Chinese medicine companies to increase investment in research and developme.
However, innovation is difficult, especially because of the particularity of the product itself, innovative Chinese medicines are even more difficult to devel.
The industry believes that as the State Food and Drug Administration has successively issued a series of documents to promote the registration and application of new Chinese medicines, it is conducive to encouraging pharmaceutical companies to innovate more Positive and clear, the innovation of traditional Chinese medicine will usher in a new situation in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In the first half of the year, it achieved an operating income of 326 billion yuan and a non-net profit of 188 million yuan attributable to the pare.
The research and development investment was 84389 million yuan, a year-on-year increase of 22
Under the continuous investment in research and development, Zhongsheng Pharmaceutical has a steady development momentum, of which the Chinese patent medicine business achieved sales of 853 million yuan, a year-on-year increase of 7
It is reported that the company also attaches great importance to the secondary development of traditional Chinese medicine and the development of high-end high-quality decoction piec.
In addition, the traditional Chinese medicine production workshop of the first phase of its Zhaoqing production base project has been officially put into operation, and the second phase of the traditional Chinese medicine extraction workshop is undergoing civil engineering construction as plann.
The construction of this project will help the company to grasp the cooperation opportunities of major industrial projects such as biomedicine and modern Chinese medicine, and consolidate the advantages of the pharmaceutical industry cha.
The near future is the performance disclosure period for the first half of 202 The semi-annual reports of traditional Chinese medicine companies are being released one after another, and the R&D investment situation has surfac.
On the whole, due to the influence of the centralized procurement of proprietary Chinese medicines and the promotion of the national policy to encourage the innovative development of traditional Chinese medicines, many traditional Chinese medicine companies actively invested in innovation and transformation in the first half of the year, and their R&D investment increased significant.
In addition to Zhongsheng Pharmaceutical, the annual report also shows that Chinese medicine companies have increased their enthusiasm for R&D investme.
For example, Yunnan Baiyao intends to increase R&D investment in recent yea.
On June 27, the company stated on the investor interaction platform that in recent years, the company has continued to increase R&D investment in various business secto.
From 2017 to 2021, the company's R&D investment amounts were 84 million yuan, 110 million yuan, 174 million yuan, 181 million yuan, and 331 million yu.
Pien Tze Huang is also accelerating the research and development of new drugs, continuously increasing investment, and carrying out the secondary development of advantageous varieties with Pien Tze Huang as the core, as well as the research and development of new products such as innovative traditional Chinese medicines, classic prescriptions, and innovative chemical dru.
At the beginning of this year, in order to further expand production capacity, enrich product varieties, increase R&D investment and market development efforts, the company also plans to spend more than 4 billion yuan to invest in capacity expansion projects to further improve the company's automation and intelligence lev.
Product quality management efficiency, fully meet market demand, and ensure long-term and stable development of the enterprise
In 2021, Pien Tze Huang's R&D investment will increase by 1052% year-on-ye.
In addition, in 2021, the R&D investment will increase by more than 100% year-on-year, such as Jichuan Pharmaceutic.
The company's research and development expenses in 2021 will be 523 million yuan, accounting for 86% of reven.
It is reported that in 2021, Jichuan Pharmaceutical will be based on traditional Chinese medicine, generic drugs, and improved new dru.
Drug production approval for Gongliuqing table.
Jichuan Pharmaceutical stated that it will increase investment in research and development, enrich product lines, and strive to improve sustainable development and profitabili.
According to data from Flush, among the listed Chinese medicine companies that disclosed their 2021 annual reports, more than half of the companies’ R&D investments have achieved year-on-year grow.
Behind the increasing investment in research and development by pharmaceutical companies, it can be seen that innovation has become an urgent issue facing Chinese medicine companies, forcing Chinese medicine companies to increase investment in research and developme.
However, innovation is difficult, especially because of the particularity of the product itself, innovative Chinese medicines are even more difficult to devel.
The industry believes that as the State Food and Drug Administration has successively issued a series of documents to promote the registration and application of new Chinese medicines, it is conducive to encouraging pharmaceutical companies to innovate more Positive and clear, the innovation of traditional Chinese medicine will usher in a new situation in the futu.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
